文献速递妇女保健预防保健、筛查与疫苗

美国女性致癌性人乳头瘤病毒感染个人风险评分(PRO-HPV)的开发与验证

Developing and validating the Personal Risk of Oncogenic Human Papillomavirus infection score in US Women.
PubMed 文献 · Fam Pract · 2019-01-01

评分可将女性分为低危(<20%)、平均危(20-30%)和高危(>30%)三组,并在2013-14队列中前瞻性验证,校准良好,区分度中等(c-statistics 0.67-0.68)。

要点

  • PRO-HPV25和PRO-HPV30评分基于六项自我报告变量,分别适用于25-59岁和30-59岁女性。
  • 评分将HRHPV感染风险分为低危(<20%)、平均危(20-30%)和高危(>30%)三组。
  • 评分在2013-14队列中验证校准良好,区分度中等(c-statistics 0.67-0.68)。

核心结论

  • PRO-HPV风险评分可识别生殖道HRHPV感染低危、平均危和高危女性群体,可用于低资源环境优先筛查或个体化筛查间隔。

研究设计与样本

  • 2017年开展的横断面分析,使用2005-14年美国国家健康与营养调查(NHANES)数据,纳入7337名25-59岁女性和6300名30-59岁女性。
  • 预测变量为生殖健康实践、风险行为及人口学变量,结局为21种生殖道HRHPV基因型中任一阳性。
  • 2005-12队列作为训练集和测试集开发评分,2013-14队列用于验证最终评分。

主要发现

  • 开发了两种含六项自我报告变量的两点评分:PRO-HPV25(25-59岁)和PRO-HPV30(30-59岁)。
  • 评分在2013-14队列中前瞻性验证,预测与观察的HRHPV感染率校准良好。
  • 评分的区分度中等,c-statistics为0.67-0.68。

关键数值与推荐

  • 风险分组阈值:低危<20%,平均危20-30%,高危>30%。
  • PRO-HPV25适用于25-59岁女性,PRO-HPV30适用于30-59岁女性。

临床怎么用

  • 在低资源环境中可利用PRO-HPV评分对女性进行风险分层,优先安排宫颈癌筛查。
  • 可根据评分结果个体化调整宫颈癌筛查间隔。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Determining risk scores for genital high-risk human papillomavirus (HRHPV) infection in women will support more efficient cervical cancer screening strategies. OBJECTIVE: We developed and validated point scores to predict the likelihood of any genital HRHPV infection in women. METHODS: We conducted the cross-sectional analysis in 2017 and used data from the 2005-14 US National Health and Nutrition Examination Survey (7337 women aged 25-59 years; 6300 women aged 30-59 years). Predictors were reproductive health practices, risk behaviors and demographic variables. The outcome was a positive result for any of the 21 genital HRHPV genotypes. The 2005-12 cohorts were used as training and testing sets to develop scores that best classified women into three risk groups: low risk (<20%), average risk (20-30%) and high risk (>30%). The 2013-14 cohort was used to validate the final scores. RESULTS: Two-point scores with six self-reported variables were created to predict any HRHPV risks for the two age groups: the Personal Risk of Oncogenic HPV (PRO-HPV25) for women aged 25-59 years old and PRO-HPV30 for women aged 30-59 years old. The scores were successfully prospectively validated, with good calibration with regards to the predicted and observed rates of HRHPV infection. The scores had fair discrimination (c-statistics: 0.67-0.68). CONCLUSION: The PRO-HPV risk scores can identify groups at low, average and high risk of genital HRHPV infection. This information can be used to prioritize women for cervical cancer screening in low-resource settings or to personalize screening intervals.

来源:Fam Pract,查看原文。版权归原作者所有。

引用

  1. Thai TN, Bui TC, Ebell MH, et al. Developing and validating the Personal Risk of Oncogenic Human Papillomavirus infection score in US Women. Fam Pract. 2019. PMID: 30239658. doi:10.1093/fampra/cmy091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。